Evaxion A (EVAX) Enterprise Value (2019 - 2026)
Evaxion A (EVAX) reported Enterprise Value of -$18.4 million for Q1 2026, down 3.35% on a YoY basis from -$19.1 million in Q1 2025, and up 20.63% quarter-over-quarter from -$23.2 million in Q4 2025.
Evaxion A (EVAX) Enterprise Value (2019 - 2026) Analysis & Trends
Evaxion A has reported Enterprise Value for 8 years, with the latest figure at -$18.4 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 3.35% year-over-year to -$18.4 million; the trailing twelve-month figure through Mar 2026 stood at -$18.4 million (down 3.35% YoY), and the FY2025 full-year result was -$23.2 million, down 290.36% from the prior year.
- Enterprise Value for Q1 2026 stood at -$18.4 million, up from -$23.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$11731.0 in Q1 2024, with the low at -$31.4 million in Q1 2022.
- Historically, Enterprise Value has averaged -$13.3 million across 5 years, with a median of -$11.9 million in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 99.89% — and 2025, when it plunged 152001.27%.
- Evaxion A's Enterprise Value stood at -$13.2 million in 2022, then surged by 57.65% to -$5.6 million in 2023, then retreated by 6.61% to -$6.0 million in 2024, then plunged by 290.36% to -$23.2 million in 2025, then gained by 20.63% to -$18.4 million in 2026.
- The last three Enterprise Value figures came in at -$18.4 million (Q1 2026), -$23.2 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | -8.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.44 Mn |
| Dec 31, 2025 | -23.23 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Jun 30, 2025 | -14.75 Mn |
| Mar 31, 2025 | -17.84 Mn |
| Dec 31, 2024 | -5.95 Mn |
| Jun 30, 2024 | -7.99 Mn |
| Mar 31, 2024 | -11,731.00 |
| Dec 31, 2023 | -5.58 Mn |
| Sep 30, 2023 | -2.61 Mn |
| Jun 30, 2023 | -7.12 Mn |
| Mar 31, 2023 | -10.24 Mn |
| Dec 31, 2022 | -13.18 Mn |
| Sep 30, 2022 | -17.85 Mn |
| Jun 30, 2022 | -25.25 Mn |
| Mar 31, 2022 | -31.41 Mn |
| Dec 31, 2021 | -32.17 Mn |
| Sep 30, 2021 | -11.94 Mn |
| Jun 30, 2021 | -18.80 Mn |
| Mar 31, 2021 | -26.96 Mn |